FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214544024> ?p ?o ?g. }

• W4214544024 abstract "Abstract Background: New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide which reconstitutes gut microbiota, reduces neuroinflammation, decreases amyloid deposition, and improves cognition in AD animal models. The first phase 3 clinical trial of GV-971 has been completed in China. Methods: We conducted a phase 3, double-blind, placebo-controlled trial in participants with mild-to-moderate AD to assess GV-971 efficacy and safety. Participants were randomized to placebo or GV-971 (900 mg) for 36 weeks. The primary outcome was the drug-placebo difference in change from baseline on the 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog12). Secondary endpoints were drug-placebo differences on the Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, and Neuropsychiatric Inventory (NPI). Safety and tolerability were monitored. Results: 818 participants were randomized: 408 to GV-971 and 410 to placebo. A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time-point, measurable at the week 4 visit and continuing throughout the trial. The difference between groups in change from baseline was −2.15 points (95% confidence interval, −3.07 to −1.23; P<0.0001; effect size 0.531) after 36 weeks treatment. Treatment-emergent adverse event incidence was comparable between active treatment and placebo (73.9%, 75.4%). Two deaths determined to be unrelated to drug effects occurred in the GV-971 group. Conclusions: GV-971 demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well tolerated. Trial registration: ClinicalTrials.gov, NCT02293915. Registered on November 19, 2014." @default.
• W4214544024 created "2022-03-02" @default.
• W4214544024 creator A5003759585 @default.
• W4214544024 creator A5004794322 @default.
• W4214544024 creator A5005578112 @default.
• W4214544024 creator A5006718110 @default.
• W4214544024 creator A5007553144 @default.
• W4214544024 creator A5009010657 @default.
• W4214544024 creator A5009318195 @default.
• W4214544024 creator A5009403353 @default.
• W4214544024 creator A5009590736 @default.
• W4214544024 creator A5009995003 @default.
• W4214544024 creator A5011164088 @default.
• W4214544024 creator A5012834626 @default.
• W4214544024 creator A5014886144 @default.
• W4214544024 creator A5015330477 @default.
• W4214544024 creator A5015760127 @default.
• W4214544024 creator A5017541508 @default.
• W4214544024 creator A5017763246 @default.
• W4214544024 creator A5017947172 @default.
• W4214544024 creator A5018211821 @default.
• W4214544024 creator A5019053897 @default.
• W4214544024 creator A5019115968 @default.
• W4214544024 creator A5019736792 @default.
• W4214544024 creator A5019837427 @default.
• W4214544024 creator A5020553004 @default.
• W4214544024 creator A5022721646 @default.
• W4214544024 creator A5023893251 @default.
• W4214544024 creator A5025467257 @default.
• W4214544024 creator A5026938141 @default.
• W4214544024 creator A5027255941 @default.
• W4214544024 creator A5027313468 @default.
• W4214544024 creator A5029257310 @default.
• W4214544024 creator A5029969638 @default.
• W4214544024 creator A5030965514 @default.
• W4214544024 creator A5031328587 @default.
• W4214544024 creator A5031870274 @default.
• W4214544024 creator A5032334740 @default.
• W4214544024 creator A5032950722 @default.
• W4214544024 creator A5033259787 @default.
• W4214544024 creator A5034308015 @default.
• W4214544024 creator A5034826329 @default.
• W4214544024 creator A5038350185 @default.
• W4214544024 creator A5038506863 @default.
• W4214544024 creator A5042161240 @default.
• W4214544024 creator A5043821915 @default.
• W4214544024 creator A5046174386 @default.
• W4214544024 creator A5050112775 @default.
• W4214544024 creator A5052314930 @default.
• W4214544024 creator A5052938144 @default.
• W4214544024 creator A5053677698 @default.
• W4214544024 creator A5054659867 @default.
• W4214544024 creator A5057745458 @default.
• W4214544024 creator A5057850753 @default.
• W4214544024 creator A5057917952 @default.
• W4214544024 creator A5058791281 @default.
• W4214544024 creator A5060487287 @default.
• W4214544024 creator A5060812392 @default.
• W4214544024 creator A5061074781 @default.
• W4214544024 creator A5062278589 @default.
• W4214544024 creator A5064310459 @default.
• W4214544024 creator A5064842058 @default.
• W4214544024 creator A5065346031 @default.
• W4214544024 creator A5065990541 @default.
• W4214544024 creator A5068531085 @default.
• W4214544024 creator A5069223999 @default.
• W4214544024 creator A5069598030 @default.
• W4214544024 creator A5070421783 @default.
• W4214544024 creator A5072608669 @default.
• W4214544024 creator A5073105215 @default.
• W4214544024 creator A5073568638 @default.
• W4214544024 creator A5074494657 @default.
• W4214544024 creator A5076560470 @default.
• W4214544024 creator A5076699095 @default.
• W4214544024 creator A5077605804 @default.
• W4214544024 creator A5078984583 @default.
• W4214544024 creator A5079527792 @default.
• W4214544024 creator A5079964310 @default.
• W4214544024 creator A5082465261 @default.
• W4214544024 creator A5082774034 @default.
• W4214544024 creator A5085122083 @default.
• W4214544024 creator A5085142676 @default.
• W4214544024 creator A5085604962 @default.
• W4214544024 creator A5085744380 @default.
• W4214544024 creator A5088012417 @default.
• W4214544024 creator A5088964405 @default.
• W4214544024 creator A5089812226 @default.
• W4214544024 date "2020-11-20" @default.
• W4214544024 modified "2023-09-27" @default.
• W4214544024 title "A 36-week Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer's Dementia" @default.
• W4214544024 doi "https://doi.org/10.21203/rs.3.rs-108812/v1" @default.
• W4214544024 hasPublicationYear "2020" @default.
• W4214544024 type Work @default.
• W4214544024 citedByCount "0" @default.
• W4214544024 crossrefType "posted-content" @default.
• W4214544024 hasAuthorship W4214544024A5003759585 @default.
• W4214544024 hasAuthorship W4214544024A5004794322 @default.
• W4214544024 hasAuthorship W4214544024A5005578112 @default.
• W4214544024 hasAuthorship W4214544024A5006718110 @default.
• W4214544024 hasAuthorship W4214544024A5007553144 @default.

• next